CL2011000065A1 - Veterinary formulation for the prevention and elimination of infection by strains of e. coli stec, which comprises a recombinant plasmid encoding a virulence factor and cationic liposome as a vehicle, use of said formulation to preferably treat cattle and pigs. - Google Patents

Veterinary formulation for the prevention and elimination of infection by strains of e. coli stec, which comprises a recombinant plasmid encoding a virulence factor and cationic liposome as a vehicle, use of said formulation to preferably treat cattle and pigs.

Info

Publication number
CL2011000065A1
CL2011000065A1 CL2011000065A CL2011000065A CL2011000065A1 CL 2011000065 A1 CL2011000065 A1 CL 2011000065A1 CL 2011000065 A CL2011000065 A CL 2011000065A CL 2011000065 A CL2011000065 A CL 2011000065A CL 2011000065 A1 CL2011000065 A1 CL 2011000065A1
Authority
CL
Chile
Prior art keywords
formulation
pigs
strains
elimination
infection
Prior art date
Application number
CL2011000065A
Other languages
Spanish (es)
Inventor
Contreras Angel Rivera Concha Alejandra Onate
Original Assignee
Univ Concepcion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Concepcion filed Critical Univ Concepcion
Priority to CL2011000065A priority Critical patent/CL2011000065A1/en
Publication of CL2011000065A1 publication Critical patent/CL2011000065A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formulación veterinaria para la prevención y eliminación de infección por cepas de E. Coli Stec, que comprende un plásmido recombinante que codifica el factor de virulencia Efa A1 y liposoma catiónico como vehículo, uso de dicha formulación para tratar preferentemente bovinos y porcinos.Veterinary formulation for the prevention and elimination of infection by strains of E. Coli Stec, which comprises a recombinant plasmid encoding the Efa A1 virulence factor and cationic liposome as a vehicle, use of said formulation to preferably treat cattle and pigs.

CL2011000065A 2011-01-11 2011-01-11 Veterinary formulation for the prevention and elimination of infection by strains of e. coli stec, which comprises a recombinant plasmid encoding a virulence factor and cationic liposome as a vehicle, use of said formulation to preferably treat cattle and pigs. CL2011000065A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CL2011000065A CL2011000065A1 (en) 2011-01-11 2011-01-11 Veterinary formulation for the prevention and elimination of infection by strains of e. coli stec, which comprises a recombinant plasmid encoding a virulence factor and cationic liposome as a vehicle, use of said formulation to preferably treat cattle and pigs.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2011000065A CL2011000065A1 (en) 2011-01-11 2011-01-11 Veterinary formulation for the prevention and elimination of infection by strains of e. coli stec, which comprises a recombinant plasmid encoding a virulence factor and cationic liposome as a vehicle, use of said formulation to preferably treat cattle and pigs.

Publications (1)

Publication Number Publication Date
CL2011000065A1 true CL2011000065A1 (en) 2011-04-15

Family

ID=66221386

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000065A CL2011000065A1 (en) 2011-01-11 2011-01-11 Veterinary formulation for the prevention and elimination of infection by strains of e. coli stec, which comprises a recombinant plasmid encoding a virulence factor and cationic liposome as a vehicle, use of said formulation to preferably treat cattle and pigs.

Country Status (1)

Country Link
CL (1) CL2011000065A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10155950B2 (en) 2014-02-28 2018-12-18 Bayer Animal Health Gmbh Immunostimulatory plasmids

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10155950B2 (en) 2014-02-28 2018-12-18 Bayer Animal Health Gmbh Immunostimulatory plasmids
US10851379B2 (en) 2014-02-28 2020-12-01 Bayer Animal Health Gmbh Immunostimulatory plasmids

Similar Documents

Publication Publication Date Title
CL2014002087A1 (en) Chewable veterinary composition comprising as active agent an isoxazoline derivative compound; and its use for the treatment and / or prevention of an infestation and / or infection by parasites in an animal.
UY34750A (en) ? COMPOUNDS FOR HIV TREATMENT, COMPOSITIONS, PREPARATION METHODS, INTERMEDIARIES AND THERAPEUTIC METHODS ?.
GT201600183A (en) ORGANIC COMPOUNDS OF MONOBACTAM FOR THE TREATMENT OF BACTERIAL INFECTIONS
MX2019012979A (en) COMPOSITIONS FOR ORAL CARE.
AR091837A1 (en) COMPOUNDS FOR DIRECTED IMMUNOTHERAPY
CL2015001731A1 (en) Autotaxin inhibitor compounds; pharmaceutical composition and combination; and use in the treatment of diseases such as fibrosis, pruritus, cancer, among others.
PA8740901A1 (en) ORGANIC COMPOUNDS
ECSP14017269A (en) COMPOUNDS TO TREAT SPINAL MUSCULAR ATROPHY
BR112013033319A2 (en) composition comprising chitosan, glucosamine and amino acids for agricultural use
MX358514B (en) Compounds for treating spinal muscular atrophy.
BR112013024794A2 (en) thermosensitive, mucoadhesive or dermoadhesive formulations, and penetration enhancement for topical therapeutic release
UY35055A (en) PHARMACEUTICAL COMBINATIONS THAT INCLUDE DUAL BINDERS OF ANGIOPOYETINA-2 / DLL4 AND ANTI-VEGF AGENTS
MX2014011855A (en) SYSTEMS AND METHODS TO TREAT AN ADVERSE PHARMACODYNAMIC RESPONSE INDUCED BY OPIOIDES.
CU20160072A7 (en) TIENOPIRIMIDINS AS MKNK1 AND MKNK2 INHIBITORS
DOP2017000146A (en) PIRAZOLPIRIDINAMINS AS INHIBITORS OF MKNK1 AND MKNK2
CL2014003565A1 (en) Use of 2-methylene-19-nor- (20s) -1alpha, 25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism.
BRPI1006875A2 (en) pharmaceutical composition, bacteria, use of live bacteria, and methods for treating an animal.
UY33833A (en) Robo1-Fc fusion protein for use in the treatment of hepatocarcinoma
PL2852293T3 (en) Treatment of poultry, pigs or fish for reducing the feed conversion ratio or increasing their bodyweight gain
MX2020009966A (en) Dosage forms and therapeutic uses l-4-chlorokynurenine.
MX2015007128A (en) New treatments with triazines.
MX2015016628A (en) METHOD TO TREAT INTRACELLULAR INFECTION.
CO7121334A2 (en) Vesicular formulations
CL2014003185A1 (en) Low viscosity preformulation comprising pasireotide, somatostatin receptor agonist; preformulation preparation process; pharmaceutical kit; Use to treat cushing disease or acromegaly.
DOP2010000406A (en) NIFURTIMOX FOR THE TREATMENT OF DISEASES CAUSED BY TRICHOMONADIDA